# Post Marketing Surveillance(PMS) Study of Lorviqua in Korea

> **NCT05599412** · — · RECRUITING · sponsor: **Pfizer** · enrollment: 600 (estimated)

## Conditions studied

- Metastatic ALK+ Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Lorviqua

## Key facts

- **NCT ID:** NCT05599412
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2023-05-22
- **Primary completion:** 2028-01-31
- **Final completion:** 2028-01-31
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05599412

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05599412, "Post Marketing Surveillance(PMS) Study of Lorviqua in Korea". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05599412. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*